Jonathan Birchall - 08 Nov 2021 Form 4 Insider Report for PhaseBio Pharmaceuticals Inc

Role
Chief Commercial Officer
Signature
/s/ John P. Sharp, Attorney-in-fact
Issuer symbol
N/A
Transactions as of
08 Nov 2021
Net transactions value
+$842,500
Form type
4
Filing time
09 Nov 2021, 19:46:54 UTC
Next filing
28 Feb 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PHASQ Employee Stock Option (right to buy) Award $842,500 +250,000 $3.37* 250,000 08 Nov 2021 Common Stock 250,000 $3.37 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the option shall vest on November 8, 2022, the first anniversary of the Vesting Commencement Date, and the remainder of the shares subject to the option shall vest in equal monthly installments over 36 months on the same day of the month as the Vesting Commencement Date, subject to the reporting person's continued service through each such date.